Moore Kuehn Encourages Esperion Therapeutics, Inc. Investors to Contact Law Firm for Possible Claims Against Officers and Directors
NEW YORK, April 24, 2019 /PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street in downtown New York City, is investigating whether certain officers and directors of Esperion Therapeutics, Inc. (NASDAQ: ESPR) breached their fiduciary duties to shareholders.
According to a federal securities lawsuit, Esperion made materially false and misleading statements regarding the Company's business, operational and compliance policies. Esperion made false and/or misleading statements and/or failed to disclose that: (i) Esperion's cholesterol-lowering medication, bempedoic acid, entailed serious undisclosed safety risks, including death; and (ii) as a result of the foregoing, Esperion's public statements were materially false and misleading at all relevant times.
Esperion Therapeutics, Inc. is a public American pharmaceutical company focused on the development of bempedoic acid.
Moore Kuehn encourages shareholders to contact Fletcher Moore, Esq. by email at [email protected] or telephone at (212) 709-8245. There is no cost or obligation to you.
Moore Kuehn is a New York-based law firm with attorneys representing investors and consumers in litigation involving securities law violations, financial fraud, breaches of fiduciary duties, and other claims. For additional information about Moore Kuehn, please go to www.moorekuehn.com. ATTORNEY ADVERTISING. Prior results do not guarantee similar outcomes.
Contacts:
Moore Kuehn, PLLC
Fletcher Moore, Esq.
30 Wall Street, 8th Floor
New York, New York 10005
[email protected]
(212) 709-8245
SOURCE Moore Kuehn, PLLC
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article